0001293818 false 0001293818 2022-05-12 2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, DC 20549





Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

May 12, 2022
Date of Report (date of earliest event reported)


OpGen, Inc.

(Exact name of Registrant as specified in its charter)



(State or other jurisdiction of incorporation or organization)




File Number)



(I.R.S. Employer
Identification Number)

9717 Key West Ave, Suite 100
, MD 20850
(Address of principal executive offices)(Zip code)

(240) 813-1260
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock OPGN The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 — Results of Operations and Financial Condition


On May 12, 2022, OpGen, Inc. issued a press release announcing its first quarter financial results for the quarter ended March 31, 2022. The full text of such press release is furnished as Exhibit 99.1 to this report.


Item 9.01 —  Financial Statements and Exhibits.

(d) Exhibits



Press Release, dated May 12, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information included in Item 2.02 herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 12, 2022   OpGen, Inc.

/s/ Oliver Schacht

        Name:   Oliver Schacht
        Title:   Chief Executive Officer


EX-99.1 2 ex99x1.htm EXHIBIT 99.1

Exhibit 99.1




OpGen Reports First Quarter 2022 Financial Results and Provides Business Update


Total Q1 2022 revenues of $0.5 million
Cash position of approximately $30.7 million to reach into Q1-2023
Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT


ROCKVILLE, Md., May 12th, 2022 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.


“We are excited about our 2022 progress to date, as we continue to achieve our key milestones,” said Oliver Schacht, President & CEO of OpGen. “We started off the year with successful V&V testing of our Unyvero A30 RQ instrument, and we received positive interim data results of the Unyvero Urinary Tract Infection (UTI) Panel and we are moving forward towards completing the enrollment of the UTI clinical trial and anticipated subsequent FDA submission in the second half of 2022.”

Dr. Schacht continued, “we are executing on our key milestones and expanding and nurturing our network of partnerships and collaborations. Also, we have seen over 76% growth in direct sales in the U.S. compared to the first quarter of last year. We are excited about the year ahead and look forward to continuing the fight against antimicrobial resistance.”


First Quarter 2022 Financial Results of OpGen, Inc.


Total revenue for the first quarter of 2022 was approximately $0.47 million, compared with $0.83 million in the first quarter of 2021.
Operating expenses for the first quarter of 2022 were approximately $6.3 million, compared with $7.1 million in the first quarter of 2021.
The net loss available to common stockholders for the first quarter of 2022 was approximately $6.8 million, or $0.15 per share, compared with $14.9 million, or $0.50 per share, in the first quarter of 2021. This was primarily due to a one-time non-cash accounting charge for the Company’s warrant inducement transaction consummated in Q1-2021.
Cash and cash equivalents were approximately $30.7 million as of March 31, 2022, compared with $36.1 million as of December 31, 2021.


“Despite the continued COVID headwinds, there were bright spots in the growth in direct product sales in the U.S.” said Albert Weber, OpGen’s Chief Financial Officer. “Based on this progress and a healthy funnel of commercial opportunities, we remain optimistic about the future growth trajectory of the company in the coming quarters.”





Mr. Weber also commented on the restructuring of the repayment of the first tranche of the loan from the European Investment Bank (EIB) to OpGen’s German subsidiary, Curetis GmbH (Curetis). In April, OpGen announced that Curetis and the EIB plan to restructure the repayment of the first debt tranche which became due in April 2022. Based on this plan, the Company repaid euro 5 million in April 2022 and expects to amortize the remainder of the debt tranche of approximately euro 8.35 million (balance as of the twelve-month period beginning in May 2022) in monthly instalments of about euro 0.7 million. Mr. Weber stated that, “we’ve approached our debt repayment in a strategic way that gives us greater flexibility to manage our cash and avoid reserving large amounts of shares from our authorized common at a time when share price has been under quite some pressure.”


In the reporting quarter and year to date, the Company reached the following key milestones:

OpGen completed the successful verification and validation (V&V) and lifetime testing of its Unyvero A30 RQ instruments. This testing clears the path for the Company to finalize the new platform instrument and prepare the build of its first set of series-ready instruments which is expected to occur later this year.
In February 2022, OpGen data was published in the Journal of Clinical Microbiology for its Acuitas AMR Gene Panel Multicenter Clinical Trial.
OpGen received positive interim data results on the Unyvero UTI Panel and is on track to complete enrollment of the UTI clinical trial in the second half of 2022 and subsequently submit to the FDA.
Ares Genetics and Sandoz extended their existing master services agreement until January 31, 2025. This collaboration focuses on next-generation sequencing (NGS) and artificial intelligence (AI) assisted bioinformatics solutions for surveillance and drug repurposing efforts.
Ares Genetics commercially launched new sequencing and analysis services globally, which includes ARESid and ARESiss Express, aimed at clinical microbiologists and specialists in public health and infection prevention and control. These services are performed at Ares Genetics’ service laboratory in Vienna, Austria and are anticipated to be launched in the U.S. later this year.
OpGen’s subsidiary Curetis and the EIB plan to restructure the first tranche of debt that came due in April 2022. Subject to finalization of definitive legal agreements, Curetis repaid euro 5.0 million in cash in April 2022 and will pay the remainder of the debt tranche amounting to approximately euro 8.35 million or approximately $9 million at current foreign exchange rates. Payments of such amount will be amortized over the course of the next 12 month-period and paid in equal monthly installments of approximately euro 0.7 million in cash, beginning at the end of May 2022. Interest rates on the remaining debt would remain unchanged at 10% per annum. The equity linked percent participation interest or PPI would increase from 0.3% to 0.75% of OpGen’s market cap as of June 2024. The remaining two tranches of debt maturing in 2023 and 2024 are unchanged at this time.


In terms of fiscal 2022 guidance, OpGen expects:

U.S. direct product sales of Unyvero and Acuitas are anticipated to grow by at least 50%;
Continued growth in its European and international distribution business for Unyvero products albeit at more moderate growth rates;
Improved traction of Ares Genetics related services and software solutions business;
Overall, 2022 revenue growth of approximately around 25% to 50% year over year from the products and services business; and
Potential upside from future strategic partnering or licensing deal(s) for the Unyvero A30 platform or the Ares database assets.




Conference Call Information

OpGen’s management will host a conference call today, May 12th at 4:30 p.m. EDT, to go over the first quarter financial results and business activities, as well as answer analyst questions.


Dial-in Information

U.S. Dial-in Number: +1-877-704-4453

International Dial-in Number: +1-201-389-0920

Webcast: https://services.choruscall.com/mediaframe/webcast.html?webcastid=n37Dadqy

Conference ID: 13729189


Following the conclusion of the conference call, a replay will be available through May 26th, 2022.

The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com.

A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days. Replay access information is below:


Replay Information

U.S. Dial-in Number: +1-844-512-2921

International Dial-in Number: +1-412-317-6671

Replay PIN: 13729189


About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero®, Acuitas® AMR Gene Panel and the ARES Technology Platform including ARESdb®, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.


Forward-Looking Statements

This press release includes statements regarding the first quarter 2022 financials of OpGen and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.




 OpGen, Inc.
Consolidated Balance Sheets

   March 31, 2022  December 31, 2021
Current assets          
Cash and cash equivalents  $30,653,410   $36,080,392 
Accounts receivable, net   265,885    1,172,396 
Inventory, net   1,361,221    1,239,456 
Prepaid expenses and other current assets   1,212,195    1,250,331 
Total current assets   33,492,711    39,742,575 
Property and equipment, net   3,721,720    4,011,748 
Finance lease right-of-use assets, net   50,756    90,467 
Operating lease right-of-use assets   1,706,346    1,814,396 
Goodwill   7,316,883    7,453,007 
Intangible assets, net   14,054,168    14,530,209 
Strategic inventory   3,448,808    3,472,337 
Other noncurrent assets   468,041    551,794 
Total assets  $64,259,433   $71,666,533 
Liabilities and Stockholders’ Equity          
Current liabilities          
Accounts payable  $865,440   $1,307,081 
Accrued compensation and benefits   1,695,557    1,621,788 
Accrued liabilities   1,582,882    1,965,845 
Current maturities of long-term debt   14,394,824    14,519,113 
Short-term finance lease liabilities   26,462    43,150 
Short-term operating lease liabilities   447,710    459,792 
Total current liabilities   19,012,875    19,916,769 
Long-term debt, net   7,955,483    7,176,251 
Derivative liabilities   114,804    228,589 
Long-term finance lease liabilities   2,803    3,644 
Long-term operating lease liabilities   2,860,703    2,977,402 
Other long-term liabilities   141,631    146,798 
Total liabilities   30,088,299    30,449,453 
Stockholders’ equity          
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at March 31, 2022 and December 31, 2021, respectively   —      —   
Common stock, $0.01 par value; 100,000,000 shares authorized; 46,557,750 and 46,450,250 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively   465,578    464,503 
Additional paid-in capital   275,949,034    275,708,490 
Accumulated deficit   (242,345,255)   (235,541,539)
Accumulated other comprehensive income   101,777    585,626 
Total stockholders’ equity   34,171,134    41,217,080 
Total liabilities and stockholders’ equity  $64,259,433   $71,666,533 



OpGen, Inc.
Consolidated Statements of Operations and Comprehensive Loss
   Three Months Ended March 31,
   2022  2021
Product sales  $366,052   $613,918 
Laboratory services   42,929    97,726 
Collaboration revenue   60,764    118,072 
Total revenue   469,745    829,716 
Operating expenses          
Cost of products sold   291,997    554,054 
Cost of services   30,562    104,984 
Research and development   2,316,441    2,813,491 
General and administrative   2,625,053    2,663,657 
Sales and marketing   1,051,432    899,252 
Impairment of right-of-use asset   —      55,496 
Total operating expenses   6,315,485    7,090,934 
Operating loss   (5,845,740)   (6,261,218)
Other (expense) income          
Warrant inducement expense   —      (7,755,541)
Interest and other income   3,121    4,925 
Interest expense   (1,269,581)   (1,164,982)
Foreign currency transaction gains   198,740    427,615 
Change in fair value of derivative financial instruments   109,744    (101,390)
Total other expense   (957,976)   (8,589,373)
Loss before income taxes   (6,803,716)   (14,850,591)
Provision for income taxes   —      —   
Net loss  $(6,803,716)  $(14,850,591)
Net loss available to common stockholders  $(6,803,716)  $(14,850,591)
Net loss per common share - basic and diluted  $(0.15)  $(0.50)
Weighted average shares outstanding - basic and diluted   46,483,694    29,485,067 
Net loss  $(6,803,716)  $(14,850,591)
Other comprehensive loss - foreign currency translation   (483,849)   (1,078,479)
Comprehensive loss  $(7,287,565)  $(15,929,070)





Oliver Schacht
President and CEO

OpGen Press Contact:
Matthew Bretzius 
FischTank Marketing and PR

OpGen Investor Contact:
Alyssa Factor
Edison Group



GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 opgn-20220512.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 opgn-20220512_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 opgn-20220512_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
May 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2022
Entity File Number 001-37367
Entity Registrant Name OpGen, Inc.
Entity Central Index Key 0001293818
Entity Tax Identification Number 06-1614015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9717 Key West Ave
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 240
Local Phone Number 813-1260
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OPGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 opgen_8k-q1_htm.xml IDEA: XBRL DOCUMENT 0001293818 2022-05-12 2022-05-12 iso4217:USD shares iso4217:USD shares 0001293818 false 8-K 2022-05-12 OpGen, Inc. DE 001-37367 06-1614015 9717 Key West Ave Suite 100 Rockville MD 20850 240 813-1260 false false false false Common Stock OPGN NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( (6%K%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "%A:Q4R9:?NNX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)\VN(J';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E'MZ?)G7K:S/ MI+S&\BM;2<>(&W:>_+JZN]\^L$YP(2I^735B*[A621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M (6%K%1E=KXB* 0 *D0 8 >&PO=V]R:W-H965T&UL MG9A=<^HV$(:OS_D5&J[:F22V! %RAC!#R$!,MX7S_:75Y)&:RU>;4K(1QY3Q-E+ULKY[)O06"CE4BY/=.9 M4/#-0IN4.QB:96 S(WA7[9HZ^/&LURNG+\1# <97XJI<+]E$P.CH%2)92J4E5H1(Q:7K1']=L7. M?4#QQ.]2K.W>-?%3F6O]Z@?W\64K]$0B$9'S$AP^WL18)(E7 HZ_=Z*M\IT^ M_R)V$RH (YW8XB]9;Y_M M=%HDRJW3Z2X8"%*IMI_\?9>(O0#:/Q# =@&LX-Z^J*"\YHX/!T:OB?%/@YJ_ M**9:1 .<5+XJ4V?@6PEQ;CC6;\(, @=2_D80[<*NMF'L0-@#WQ#*3@@+&?MW M= )04K*5@AU\8HR)^CN74&ZO07(MDN)=N%9.> Y+6.1V:;3-1-$ _O MGWY'(#HE1 =5&0%!7%#<)GQ91X''+WAB!<)Q7G*<'Y>,B3!2Q^1&Q03:I38O MN-*N\%^_?&DH?;=$ZZ*"-\I)MR&W,A'D,4_G]=V(:X0A/6WWVMT>PM,K>7K' M\#R+I?3-"#E[Y&EMHG"=I^Q.J!-RKZ(SA*I?4O6/H1I##0U/0#46[^2[V-1Q MX4HA)(M=M/NTCV!=E%@7QV#-^#NYCX%-+F3$"[<]7$I<,>R>TB[MA/0=A M%%R =5"0:F&@N*/_T!'D9++2"ENI&D3ZM'U*617"5)AY6+0 ,M^B)$:<1 MI$? [VN['80=&>PUGQ:+^OHUZ#625:[/<(O^#]F]M3F0-0+BLHV >WMRW)IG MTL&>3"]@O_?3_&X*I S_%T"J?9[@QSPR/?8M--^E< MUS98@\#3Y.X1(ZE,G>$&_)$5K;A:BH/;Q0:AQ]'T>O0KQE2Y.3O*S6]2 M898^2W>@X%;>)3*NZNN'"Q[LJ6#OX.D/\0_S MXBPZUPY.ML7E2G#H=_\ ?+_0VGT,_/&V_._$\!]02P,$% @ A86L5)^@ M&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8 MMD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2 M_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQD MB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G M8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E M#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-C MT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/C MO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,, MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@ M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$ M% @ A86L5)>*NQS $P( L !?3T\$MP>:4#M.*2V MBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV MX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!E MK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3 M(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,. M]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$ M% @ A86L5"0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*] M:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8V MP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X! M4$L#!!0 ( (6%K%1ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-= M+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5 MA4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0 M]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K M'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+* M&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>= M(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( (6%K%1E=KXB M* 0 *D0 8 " @0T( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "%A:Q4 M99!YDAD! #/ P $P @ %U$@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" "_$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://opgen.com/role/Cover Cover Cover 1 false false All Reports Book All Reports opgen_8k-q1.htm ex99x1.htm opgn-20220512.xsd opgn-20220512_lab.xml opgn-20220512_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "opgen_8k-q1.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "opgen_8k-q1.htm" ] }, "labelLink": { "local": [ "opgn-20220512_lab.xml" ] }, "presentationLink": { "local": [ "opgn-20220512_pre.xml" ] }, "schema": { "local": [ "opgn-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OPGN", "nsuri": "http://opgen.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "opgen_8k-q1.htm", "contextRef": "From2022-05-12to2022-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://opgen.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "opgen_8k-q1.htm", "contextRef": "From2022-05-12to2022-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001079973-22-000577-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-22-000577-xbrl.zip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end